VC Fund
🇪🇺 Kurma Biofund III FPCI
Kurma Partners SA · Multi-Country
Fund size
EUR 160M
Focus
Health & Bio
EIF sector
Life Science
About Kurma Biofund III FPCI
Kurma Biofund III is an early-stage life sciences venture capital fund managed by Kurma Partners, based in Paris. The 2020-vintage fund of around EUR 160M backs European biotech companies, particularly in rare diseases, and has exited Amolyt Pharma to AstraZeneca and Emergence Therapeutics to Eli Lilly.
EUACC IntelligenceFree preview
EUACC Intelligence
Ask about Kurma Biofund III FPCI
Get instant answers about Kurma Biofund III FPCI and how it fits your raise.